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Abstract 
The structurally unique polyazole antibiotic goadsporin contains six heteroaromatic oxazole 
and thiazole rings integrated into a linear array of amino acids that also contains two 
dehydroalanine residues. An efficient total synthesis of goadsporin is reported in which the 
key steps are the use of rhodium(II)-catalyzed reactions of diazocarbonyl compounds to 
generate the four oxazole rings, which demonstrates the power of rhodium carbene chemistry 
in organic chemical synthesis. 
Goadsporin (1) is a secondary metabolite of Streptomyces sp. 
TP-A0584, a soil-derived actinomycete bacterium, and 
was first isolated and characterized by detailed NMR 
spectroscopic studies in 2001 by Onaka et al.[1] The 
natural product contains four oxazole and two thiazole 
rings incorporated within a linear array of amino acids that 
interestingly also contains two dehydroalanine residues 
and N-terminal acetylation. Belonging to the class of 
ribosomally synthesized and post-translationally modified 
peptides (RiPPs), goadsporin can further be classed as a 
thiazole/oxazole-modified microcin (TOMM), within 
which it is specifically classified as a linear azol(in)e-
containing peptide (LAP).[2] The biosynthesis of 
goadsporin has been fully elucidated; it originates from a 
sequence of 19 L-amino acids 
(ATVSTILCSGGTLSSAGCV), with each of the aromatic 
heterocycles resulting from the condensation of two amino 
acids.[3] The two dehydroalanine residues have recently 
been proposed to be formed through the glutamylation of 
serine, followed by glutamate elimination.[4] Goadsporin 
has been reported as a potential antibiotic, showing growth 
inhibition against Streptomycetes strains when present at high 
concentrations,[1a] including against S. scabies (MIC=0.2 
μg mL−1), the causative organism of potato scab, which is 
an economically important agricultural disease. It also 
induces sporulation and the production of secondary 
metabolites in a range of other Streptomyces strains,[1a] and 
although the mechanism of action is unknown, the reasons 
for immunity in the producing strain have been 
investigated.[1c] In continuation of our interest in the 
synthesis and properties of post-translationally modified 
peptide antibiotics such as the amythiamicins,[5] 
telomestatin,[6] and plantazolicin,[7] we embarked upon a 
total synthesis of goadsporin. We herein report the first 
synthesis of this complex polyazole antibiotic in which the 
four five-membered oxazole rings of the natural product 
are formed from simple precursors, such as carboxamides 
or nitriles, as facilitated by metallocarbene chemistry. 
Our synthetic strategy involves protection of the serine 
side chain alcohol and the C-terminal valine carboxylic 
acid with a tert-butyl ether and ester, respectively, 
orthogonal to silyl protection of the two serine residues 
that will serve as precursors to the dehydroalanine 
functionalities. Disconnection at a central amide bond in 
the protected compound 2 leads to the two 
fragments 3 and 4, adorned with suitable protecting groups, 
which can both be broken down further at an amide bond 
(Scheme 1) to give four approximately equally sized 
fragments. 
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Retrosynthetic analysis of goadsporin 1 via protected form 2, 
which is split into the left- and right-hand fragments 3 and 4. 
TBDPS=tert-butyldiphenylsilyl. 
Although some of the building blocks required for the 
synthesis of goadsporin are readily available 
proteinogenic L-amino acids, the heterocyclic components 
need to be accessed. Whilst the two thiazoles should be 
approachable through the well-established Hantzsch 
reaction, we elected to synthesize the four oxazoles by 
using rhodium carbene chemistry, a mild and versatile 
method used previously in the synthesis of azole-
containing natural products.[5-7] Reaction of 
diazocarbonyl compounds with catalytic amounts of 
rhodium(II) complexes forms an intermediate 
metallocarbene, which can undergo an N−H insertion 
reaction into a carboxamide, followed by cyclodehydration 
to give the heteroaromatic oxazole. Alternatively, the steps 
can be reversed, with the carboxamide dehydrated to a 
nitrile that reacts to give substituted oxazoles directly 
(Scheme 2).[8] Both methods are used in the present study, 
with oxazoles 7, 11, and 20 produced through N−H insertion 
(Scheme 3 and Scheme 5), and oxazole 21 produced 
through nitrile addition (Scheme 5). 
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Construction of oxazole rings from carboxamides or nitriles using 
rhodium carbene chemistry. 
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Synthesis of bis-oxazole 12. Reagents and conditions: a) 
Rh2(OAc)4, methyl 2-diazo-3-oxobutanaote 6, CHCl3, 80 °C, 16 h, 
56 %; b) NEt3, PPh3, I2, CH2Cl2, 16 h, 73 %; c) LiOH, MeOH/H2O, 
1 h, quantitative; d) valine methyl ester hydrochloride, DIPEA, 
HATU, DMF, 16 h, 82 %; e) HCl in dioxane, 4 h, 91 %; f) 
DIPEA, Ac2O, CH2Cl2, 56 h, 93 %; g) LiOH, MeOH/H2O, 4 h, 
96 %; h) Rh2(OAc)4, 6, CHCl3, 80 °C, 16 h, 73 %; i) NEt3, PPh3, I2, 
CH2Cl2, 16 h, 74 %; j) TFA/CH2Cl2 (95:5), 0 °C, 20 min, 90 %; k) 
2,6-di-tert-Bu-4-Me-pyridine, HBTU, HOAt, CH2Cl2, 16 h, 75 %; 
l) Me3SnOH, DCE, 80 °C, 16 h, quantitative. 
DIPEA=diisopropylethylamine, HATU=1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate, HBTU=N,N,N′,N′-
tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate, HOAt=1-hydroxy-7-azabenzotriazole, 
DCE=1,2-dichloroethane. 
The synthesis started with the N-terminal bis-oxazole 
fragment 12. Reaction of Boc-protected alaninamide 5 with 
diazo-β-ketoester 6 in chloroform with 2 mol % of 
rhodium(II) acetate dimer, followed by dehydration using 
iodine, triphenylphoshine, and triethylamine[9] in 
dichloromethane gave the 5-methyloxazole 7. Ester 
hydrolysis and amide coupling with valine methyl ester 
hydrochloride gave compound 8. At this point the acetyl 
group was introduced through Boc-deprotection, followed 
by acetylation (structure confirmed by X-ray 
crystallography; see the Supporting Information). 
Subsequent ester hydrolysis of the acetylated product gave 
acid 9 (Scheme 3). The second oxazole was synthesized 
analogously: rhodium(II) acetate catalyzed the reaction of 
the serine carboxamide 10, which is readily obtained in two 
steps from the Boc-serine methyl ester, to give the desired 
oxazole after cyclodehydration, which was then Boc-
deprotected with trifluoroacetic acid to give oxazole 11. 
Amide coupling between 9 and 11 under standard 
conditions (HATU, HOAt, DIPEA, and DMF) gave high 
levels of racemization of the valine residue,[10] with a d.r. 
of 1.0:0.9 as observed by HPLC. After optimization, which 
led to the use of a different base and coupling agent (2,6-
di-t-Bu-4-Me-pyridine, HBTU, and HOAt in 
dichloromethane), the bis-oxazole was successfully 
synthesized in good yield with a d.r. of 1.0:0.05. Cleavage 
of the ester using the known mild hydrolysis reagent 
trimethyltin hydroxide in 1,2-dichloroethane[11] gave the 
bis-oxazole carboxylic acid 12 (Scheme 3). 
Synthesis of the second quarter began with the conversion 
of Boc-protected leucinamide amide 13 into the 
corresponding thioamide with Lawesson's reagent in 
dichloromethane, followed by Hantzsch reaction with ethyl 
bromopyruvate under modified conditions[12] to give 
thiazole 14. Boc-deprotection and amide coupling with N-
Alloc-isoleucine gave thiazole 15 in good yield, the 
structure of which was confirmed by X-ray crystallography 
(see the Supporting Information). Hydrolysis and coupling 
to the commercially available serine (O-tert-Bu) methyl ester 
hydrochloride gave 16, which underwent deprotection using 
palladium(0) tetrakis(triphenylphosphine) with 
diethylamine in dichloromethane to give the free amine 17, 
ready for subsequent coupling with the bis-oxazole 
acid 12 (Scheme 4). 
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Synthesis of thiazole fragment 17. Reagents and conditions: a) 
Lawesson's reagent, CH2Cl2, 16 h, quantitative; b) i. KHCO3, ethyl 
bromopyruvate, DME, −40 °C—RT, 16 h, ii. TFAA, 2,6-lutidine, 
DME, −10 °C, 1 h, 76 %; c) HCl in dioxane, 1 h, 99 %; d) N-
Alloc-isoleucine, DIPEA, HATU, DMF, 16 h, 64 %; e) LiOH, 
MeOH/H2O, 2.5 h, 100 %; f) serine(O-tert-Bu) methyl ester 
hydrochloride, DIPEA, HATU, DMF, 16 h, 94 %; g) HNEt2, 
Pd(PPh3)4, CH2Cl2, 4 h, quantitative. DME=1,2-dimethoxyethane, 
TFAA=trifluoroacetic anhydride, Alloc=allyloxycarbonyl. 
In another rhodium carbene mediated step, oxazole 19 was 
formed from N-Boc-glycinamide 18(Scheme 5). Ester 
hydrolysis and coupling to leucine methyl ester 
hydrochloride gave oxazole 20. Oxazole 21 was prepared as 
previously described from N-Boc-serine methyl ester 
through rhodium carbene mediated nitrile cycloaddition,[6, 
7] and after deprotection with TFA, was O-protected 
with tert-butyldiphenylsilyl chloride to give oxazole 22. 
Amine 22 was then coupled with the acid derived from 
hydrolysis of ester 20 to give bis-oxazole 23 after removal of 
the Boc group, with no evidence for any racemization at 
the leucine α-CH. Finally, coupling with N-Alloc-glycine, 
and cleavage of the terminal ethyl ester delivered bis-
oxazole carboxylic acid 24 (Scheme 5). 
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Synthesis of bis-oxazole 24. Reagents and conditions: a) 
Rh2(OAc)4, 6, CHCl3, 80 °C, 16 h, 81 %; b) NEt3, PPh3, I2, CH2Cl2, 
16 h, 33 %; c) LiOH, MeOH/H2O, 17 h, quantitative; d) leucine 
methyl ester hydrochloride, DIPEA, HATU, DMF, 16 h, 85 %; e) 
TFA/CH2Cl2 (9:1), 0 °C to RT, 5 h, 96 %; f) TBDPSCl, NEt3, 
imidazole, CH2Cl2, 16 h, 78 %; g) LiOH, MeOH/H2O, 2 h, 93 %; 
h) DIPEA, HATU, DMF, 16 h, 71 %; i) TFA/CH2Cl2 (95:5), 0 °C, 
50 min, quantitative; j) N-Alloc-glycine, DIPEA, HATU, HOAt, 
DMF, 2 h, 78 %; k) Me3SnOH, 1,2-DCE, 80 °C, 8 h, quantitative. 
Synthesis of the C-terminal quarter began with the 
preparation of thiazole 25. Conversion of N-Boc-
glycinamide 18 into the corresponding thioamide was 
followed by Hantzsch reaction with bromopyruvic acid 
and calcium carbonate in methanol gave the desired 
thiazole-4-carboxylic acid 25 in excellent yield. Amide 
coupling to commercially available valine tert-butyl ester 
ensued smoothly. Selective removal of the Boc group in 
the presence of the tert-butyl ester proceeded with 
methanesulfonic acid in a mixture of dichloromethane/tert-
butyl acetate[13] to give the free amine, which was 
immediately coupled to N-Alloc-alanine in high yield. 
Finally, removal of the Alloc group gave the C-terminal 
thiazole 27 (Scheme 6). 
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Synthesis of thiazole 27. Reagents and conditions: a) Lawesson's 
reagent, CH2Cl2, 16 h, 84 %; b) CaCO3, bromopyruvic acid, 
MeOH, 87 h, 98 %; c) valine tert-butyl ester hydrochloride, 
DIPEA, HATU, DMF/CH2Cl2 (1:1), 3 h, 93 %; d) 
methanesulfonic acid, t-BuOAc/CH2Cl2 (1:1), 7 h, quantitative; e) 
N-Alloc-alanine, DIPEA, HATU, DMF, 16 h, 78 %; f) HNEt2, 
Pd(PPh3)4, CH2Cl2, 1.5 h, 80 %. 
With all four fragments in hand, it remained to perform the 
relevant coupling reactions. Acid 12 and amine 17 were 
coupled under HATU conditions to give bis-oxazole-
thiazole 28, the hydrolysis of which delivered acid 3. 
Likewise, acid 24 and amine 27 were coupled together to 
give bis-oxazole-thiazole 29, which was deprotected to give 
amine 4. The union of the left- and right-hand 
fragments 3 and 4 was brought about through a further 
HATU-mediated reaction to give the complete linear 
polyazole peptide 2 (Scheme 7). Double removal of the 
two silyl groups using TBAT in THF gave the 
corresponding diol, dehydration of which with 
methanesulfonyl chloride and triethylamine, followed by 
addition of DBU, installed the two dehydroalanine 
residues in the complete sequence 30. Finally, the tert-butyl 
ether and ester protecting groups were removed under 
mildly Lewis acidic conditions with zinc bromide in 
chloroform[14] to give goadsporin. Given the previously 
noted racemization of a valine α-CH, all of the the C-
terminal valine intermediates (27, 29, 4, 2, and 30) were 
carefully checked by NMR to exclude the possibility of 
racemization, even though the valine residue is not directly 
involved in any of the coupling reactions. Following 
purification by column chromatography, our synthetic 
material co-eluted with natural goadsporin by HPLC as 
shown in the Supporting Information. The proton and 
carbon NMR spectra, obtained at 500 and 800 MHz, of the 
synthetic material were fully assigned using a range of 
experiments, including NOESY (see the Supporting 
Information), and were fully consistent with the structure. 
However, there was one difference in the proton NMR 
spectrum of the synthesized sample compared with the 
data reported for the natural product, namely the α-H of 
the C-terminal valine. This variation was echoed in the 
carbon NMR spectrum, in which signals for the thiazole 
and valine at the C terminus again varied slightly from the 
reported data. Having ruled out the possibility of any 
racemization of the C-terminal valine (see above), we 
ascribe this difference to the exchangeable nature of the C-
terminal carboxylic acid of goadsporin. In light of this, a 
slight differences in pH or would cause different rates of 
exchange of the carboxylic acid, thereby resulting in a 
different chemical shift of the signals at the C 
terminus.[15] However, the NMR spectra of a mixed co-
sample of synthetic and natural material confirmed the 
presence of a single compound, thus confirming 
completion of the total synthesis of goadsporin. 
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Completion of the synthesis of goadsporin (1). Reagents and 
conditions: a) DIPEA, HATU, HOAt, DMF, 5 h, 80 %; b) 
Me3SnOH, DCE, 70 °C, 16 h, quantitative; c) DIPEA, HATU, 
HOAt, DMF, 16 h, 81 %; d) HNEt2, Pd(PPh3)4, CH2Cl2, 4 h, 77 %; 
e) DIPEA, HATU, HOAt, DMF, 5 h, 66 %; f) TBAT, THF, 4 h, 
61 %; g) MsCl, NEt3, THF, 0 °C, 3 h, then DBU, CHCl3, 0 °C, 4 h, 
36 %; h) ZnBr2, CHCl3, RT, 16 h, then 35 °C, 2 h, 66 %. 
TBAT=tetra-n-butylammonium triphenyldifluorosilicate, 
DBU=1,8-diazabicyclo[5.4.0]undec-7-ene. 
In conclusion, the rhodium carbene route described above 
not only forms the basis for the first total synthesis of the 
fascinating polyazole peptide antibiotic goadsporin, but 
also makes available a wide range fragment structures and 
intermediates that are not available through nature's 
biosynthetic machinery. 
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